Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Guerbet: 2015 annual revenue | ||||||||||||||||||||||||||||||||||
By: Nasdaq / GlobeNewswire - 10 Feb 2016 | Back to overview list |
|||||||||||||||||||||||||||||||||
Excellent level of activity in 2015 €449.4 million in revenue: +10.0% at constant exchange rates Villepinte, 10 February 2016 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and medical imaging solutions, is reporting €460.8 million in revenue for financial year 2015, representing a 12.7% increase on a like-for-like basis. At constant exchange rates, revenue grew by 10.0% to €449.4 million. Consolidated Group revenue excluding integration of CMDS (IFRS)
V
ery good activity in the fourth quarter: €117.1 million
Strong sales growth in 2015: +12.7%
Strong performance of the four business segments
Driven by Dotarem , the MRI segment grew the most in absolute value with a 21.7% increase. With €204.8 million in revenue, this segment now represents the majority of the Group's product mix, accounting for 44.4% of sales. The X-ray segment increased by 1.9% to €191.4 million. Sales benefited from a favourable volume effect from Xenetix ® . With steady sales for Lipiodol and Patent Blue V , the IRT segment continued to rise considerably at a rate of more than 40% over the financial year. The Imaging Solutions and Services (ISS) segment saw 3.8% growth, with sales amounting to €17.9 million.
Integration of the "CMDS" activity starting from 1 December 2015
2016, a year of transition for the Group
Upcoming events:
About Guerbet With nearly 90 years' experience, Guerbet is a pioneer in the contrast agent field and the global specialist of the medical imaging market. It offers a comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve the diagnosis and treatment of patients. The acquisition of Mallinckrod's "contrast media and delivery systems" (CMDS) activity has doubled its size with an expanded offering. In 2014, the combined pro forma sales of Guerbet and the CMDS activity represented approximately €800 million, with around 2,500 employees. Guerbet (GBT) is listed on NYSE Euronext Paris (Segment B - Mid Caps). For more information about Guerbet , please visit www.guerbet.com
Contacts
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: GUERBET via GlobeNewswire
HUG#1985322
|
||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
Copyright 2016 Nasdaq / GlobeNewswire | Back to overview list |